Internal Medicine, Medical Oncology · Detroit, MI
NPI
1013960384
Since 2006
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
2
Medicare group memberships
Hospitals
3
Hospital affiliations
4100 John R, Karmanos Cancer Center
Detroit, MI, 48201
Phone (800) 527-6266
Groups this clinician bills Medicare through
Medicare paid, 2024
$51K
518 services
Medicare patients, 2024
137
Average age 72
Drug cost, 2024
$2.0M
645 prescriptions
Company payments, 2025
$39K
From 12 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Ammar Sukari was code 99215 (office e&m - established), 145 times for 46 patients. In total Ammar Sukari billed 518 services in 8 codes, and Medicare paid $51K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2016-09-27.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Facility | 145 | 46 | $109.94 | $16K |
| 99214 Office E&M - Established | Facility | 120 | 54 | $74.44 | $8,933 |
| 99215 Office E&M - Established | Office | 119 | 33 | $121.05 | $14K |
| 99214 Office E&M - Established | Office | 67 | 39 | $78.29 | $5,246 |
| 99213 Office E&M - Established | Facility | 22 | 17 | $52.92 | $1,164 |
| 99205 Office E&M - New | Facility | 12 | 12 | $146.21 | $1,755 |
By year: 2022 $71K for 718 services; 2023 $53K for 563 services; 2024 $51K for 518 services.
Medicare prescription drug claims, 2024
In 2024, the drug Ammar Sukari prescribed most often to Medicare patients was Levothyroxine Sodium, with 94 prescriptions and refills. In total Ammar Sukari wrote 645 Medicare prescriptions that cost $2.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 94 | 243 | 32 | $1,342 |
| Pilocarpine Hcl Generic | 47 | 80 | 20 | $4,590 |
| Mekinist Trametinib Dimethyl Sulfoxide | 29 | 29 | Under 11 | $367K |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 27 | 27 | 18 | $407 |
| Tafinlar Dabrafenib Mesylate | 27 | 29 | Under 11 | $324K |
| Anastrozole Generic | 26 | 53 | Under 11 | $1,062 |
| Letrozole Generic | 25 | 67 | Under 11 | $710 |
| Duloxetine Hcl Generic | 19 | 49 | Under 11 | $519 |
| Sorafenib Sorafenib Tosylate | 15 | 15 | Under 11 | $78K |
| Amlodipine Besylate Generic | 14 | 38 | Under 11 | $90.94 |
| Ondansetron Hcl Generic | 14 | 14 | Under 11 | $142 |
| Lidocaine Hcl Viscous Lidocaine Hcl | 12 | 12 | Under 11 | $239 |
| Gabapentin Generic | 12 | 14 | Under 11 | $114 |
| Tukysa Tucatinib | 12 | 12 | Under 11 | $269K |
| Gavreto Pralsetinib | 12 | 12 | Under 11 | $254K |
Brand drugs: - claims; generic drugs: 464 claims; opioid claims: 37.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Ammar Sukari $39K ($38K in general payments such as food, travel and fees and $957 for research) from 12 companies. The largest payer was Daiichi Sankyo Inc. with $18K.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.